Participated · Seed · Apr 2024

LightLink is a remote Ethereum Layer 2 focused on enabling gasless transactions and a streamlined user experience to drive mass adoption of Web3. The company offers an enterprise mode that lets businesses operate gas-free so their users can transact without fees or tokens. LightLink has integrated Celestia as a Data Availability layer and expanded its proprietary stack. It became the first Optimium L2 to be listed on L2Beat. The company is preparing for a token distribution via a Liquidity Bootstrapping Pool on Fjord Foundry. LightLink plans to leverage more than 25 strategic partnerships, including Animoca Brands. Led by CEO Roy Hui, the firm intends to use recent funding to expand its development efforts. LightLink operates an L2 project focused on serving decentralized finance, metaverse, NFT and game applications. The company builds infrastructure and tools tailored to those Web3 use cases. The article positions LightLink as a specialized operator for projects in those verticals rather than a consumer-facing product. No operating metrics or revenue figures were disclosed in the report. The announcement centers on the company’s product focus and recent seed financing.

Participated · Seed · Feb 2024

Talus Network operates a new Layer-1 blockchain designed to let AI models act as fully on-chain agents that can execute tasks and manage assets without centralized intermediaries. Its infrastructure includes the Nexus protocol (currently in testnet), a no-code AI-agent builder called Talus Vision, and the consumer app Idol.fun where agents compete in social settings. The project’s native $US token, with a 10 billion total supply, debuted on multiple exchanges on 11 December and quickly climbed about 15 percent, stabilizing near $0.020. Early investors were allocated 2.2 billion tokens that unlock gradually to limit sell pressure. Backers have provided more than $10 million, valuing the project at roughly $150 million. This capital is intended to accelerate product roll-outs and attract additional developers and users to the network. Although revenue and user counts were not disclosed, initial trading interest indicates strong market traction for its AI-centric blockchain vision.

Participated · Equity · Jul 2023

Shardeum is a scalable EVM-based layer-1 blockchain that deploys dynamic state sharding. Its dynamic state sharding approach keeps gas fees low and TPS high as participation grows by performing consensus at the transaction level and lowering the computational power required for validator nodes. This consensus mechanism aims to allow anyone to run a node and increase decentralization. The company intends to use the $5.4M in new funding to expand operations and accelerate development efforts. Operating metrics on the testnet as of July 7, 2023 include over 7.4 million transactions, 820K+ accounts and more than 230K contracts deployed. Shardeum raised an $18.2M seed round in October 2022 from investors including Jane Street, Big Brain Holdings, Struck Crypto, The Spartan Group, Ghaf Capital, DFG, CoinGecko Ventures and Foresight Ventures. Shardeum is a remote, EVM-based Layer 1 blockchain that implements sharding to increase transactions per second as nodes are added while retaining atomic cross-shard composability. The protocol emphasizes low gas fees forever and leverages dynamic state sharding to balance decentralization and security. Founded by Nischal Shetty and Omar Syed, the company raised $18.2M in Seed funding. Backers include Jane Street, Struck Crypto, The Spartan Group and a broad group of institutional and angel investors. The company plans to use the funds to further enhance its dynamic sharding technology, accelerate ecosystem development, and focus on product and design improvements. It will also expand research and marketing efforts and host hackathons in India and the U.S. to incentivize developers to build on the platform.

Participated · Series A · Jun 2022

AMILI is a Singapore precision gut microbiome company founded in 2019 that builds a multi-ethnic repository of microbiome data and samples, including the only existing microbiome bank in Southeast Asia. Its core products include diagnostics, predictive algorithms and microbiome-modifying interventions powered by its proprietary analytics engine, AMILI Prime. The company licenses its database to academic institutions, biotech firms and food manufacturers to identify biomarkers and inform product formulation. AMILI also provides faecal microbiota transplants and has launched a consumer health brand, BIO & ME, offering probiotics and diagnostic tests based on its database, with planned rollouts in Southeast Asia and Hong Kong later this year. It focuses clinical research on health and wellness, oncology, and response to microbiome-based therapeutics, having conducted over 20 research studies valued at over $40 million. The company intends to use new funding to expand in Southeast Asia and the rest of Asia, pursue additional research partnerships, and further develop AMILI Prime.